Eli Lilly reported Q4 2025 revenue growth of 43% YoY and full-year revenue of $65.2B (+45% YoY), with EPS up 86% to $24.21. 2026 guidance calls for $80–$83B in revenue (+25% YoY at midpoint), driven ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly reported Q4 2025 revenue growth of 43% YoY and full-year revenue of $65.2B (+45% YoY), with EPS up 86% to $24.21. 2026 guidance calls for $80–$83B in revenue (+25% YoY at midpoint), driven ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly and Co (ISIN: US5324571083) shares rose significantly following the announcement of a $7.8 billion acquisition of Centessa Pharmaceuticals and robust Q4 earnings. The deal expands Lilly's ...
Eli Lilly & Co. research and ratings by Barron's. View LLY revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875B in cash, including an upfront payment and contingent milestone payments. The deal is expected to close in Q4 2026, subject to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results